Aluminum Oxide Arsenic Trioxide Calomel Chelidoniu
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Aluminum Oxide Arsenic Trioxide Calomel Chelidoniu
- Multi-Ingredient Heavy Metal Complex: No Repurposing Indication Identified
Multi-Ingredient Heavy Metal Complex: No Repurposing Indication Identified
One-Sentence Summary
This entry represents a 13-ingredient mixture containing multiple toxic heavy metals and botanical substances — a profile consistent with a homeopathic or traditional compound preparation. The TxGNN pipeline returned no predicted repurposing indications, and the product has no US market authorization. No supporting clinical trial or literature evidence was retrieved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indications on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no model predictions, no studies) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
There are no predicted indications to evaluate. The compound is a 13-ingredient mixture whose composition raises immediate concern: arsenic trioxide (a cytotoxic oncology drug regulated under strict protocols), calomel (mercurous chloride), mercuric iodide, and Mercurius Solubilis (a homeopathic mercury preparation), lead and lead iodide (neurotoxins with no established safe exposure level), and silver nitrate (a caustic agent). The presence of botanical entries — Chelidonium majus, Solidago virgaurea flowering top — and the Latin naming convention of “Mercurius Solubilis” strongly suggests this is a homeopathic formulation, not a conventional pharmaceutical entity.
Currently, no mechanism of action data is available. The product lacks a DrugBank ID, carries no TFDA or US approval records, and cannot be matched to a single pharmacologically characterized compound. Standard TxGNN drug repurposing pipelines operate on single-entity drugs mapped to the DrugBank knowledge graph; a 13-ingredient homeopathic mixture, particularly one without a DrugBank ID, is outside the model’s intended input domain.
The absence of any TxGNN output is therefore expected and appropriate, not a data pipeline error.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No US market authorizations exist for this product.
Safety Considerations
Several ingredients in this mixture carry well-established serious toxicity profiles:
- Arsenic trioxide: Human carcinogen; FDA-approved only for acute promyelocytic leukemia under a restricted Risk Evaluation and Mitigation Strategy (REMS). Causes QT prolongation, peripheral neuropathy, and hepatotoxicity.
- Calomel (Mercurous chloride) and Mercuric iodide: Mercury-containing compounds. Chronic exposure causes nephrotoxicity, neurotoxicity, and acrodynia. The cumulative mercury burden from three mercury-containing ingredients (calomel, mercuric iodide, Mercurius Solubilis) in a single formulation is a significant concern.
- Lead and Lead iodide: No safe level of lead exposure exists according to WHO and US CDC. Lead causes irreversible neurodevelopmental damage, nephropathy, and anaemia.
- Silver nitrate: Caustic and oxidising agent; systemic absorption causes argyria (permanent skin/tissue discolouration) and can impair renal function.
Please refer to individual component package inserts and current regulatory guidance for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no repurposing predictions for this entry, and the formulation contains multiple substances of serious and well-documented toxicological concern. There is no viable path to a repurposing evaluation as currently submitted.
To proceed, the following is needed:
- Clarify regulatory context: Confirm whether this is a homeopathic product. If so, standard drug repurposing modelling does not apply, and the regulatory pathway (e.g., OTC homeopathic monograph, FDA Compliance Policy Guide) is fundamentally different from a conventional NDA.
- Disaggregate and re-query: If the intent is to evaluate a specific active ingredient — most likely arsenic trioxide (DrugBank: DB01169) — submit it as a standalone entry through the TxGNN pipeline.
- Do not aggregate toxic ingredients: Submitting lead, mercury compounds, and arsenic trioxide as a single drug entity bypasses the safety review mechanisms designed for each toxic component individually.
- Obtain component-level safety data: Each heavy-metal-containing ingredient requires its own toxicology review before any clinical evaluation is considered.
- Regulatory opinion: Seek a pre-submission meeting with FDA or equivalent authority to clarify the product’s classification before investing further in any development or repurposing programme.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.